Dale R. Pfost, Ph.D. – Director, Cofounder and CEO

Founding CEO of five biotechnology companies—achieved 3 IPOs, 3 trade-sales and 3 companies with market capitalizations of over $2 billion: Infinitek, producer of Biomek, acquired by SmithKline Beckman (1984), Oxford GlycoSciences (IPO 1988), Orchid Biosciences (IPO 2000), Acuity Pharmaceuticals (now OPKO Health, 2007), Receptor BioLogix (sold 2009), NuMe Health (founded 2009, now MBT). Currently is the US General Partner of London-based Advent Life Sciences—a venture capital group focused entirely on life science investments in the US and Europe.



Mark Heiman, Ph.D. – Vice President of Research & Chief Scientific Officer

20+ years at Eli Lilly, served as CSO of obesity drug discovery, inventor of successful drug Lanreotide®, author of more than 100 scientific papers, helped develop 30 drug-related patents. A Fellow of the Obesity Society and serves on the editorial board of Current Medicinal Chemistry-Immunology Endocrinology and Metabolic Agents in Medicinal Chemistry and Molecular Metabolism. Recognized leader in the emerging science of the microbiome. Inventor on Microbiome Therapeutics’ patents.




John Elstrott, PhD – Chairman, Cofounder

Emeritus Executive Director of Levy Rosenblum Institute, 2013 Tulane Distinguished Entrepreneur and Social Entrepreneur of the Year, Past Chairman of Whole Foods Market, first CFO of Celestial Seasonings, Board member of multiple successful health food and supplement companies: Traditional Medicinals, Sambazon, WhiteWave Foods (Silk Soy Milk).  Named the Ernst and Young Louisiana Entrepreneur of the Year in 1997 and in 2007 awarded the Howard W. Wissner Award at the A. B. Freeman School of Business at Tulane.